Related Experiment Video
Updated: Jun 14, 2025

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Inpatient Growth in Infants Requiring Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome
Ashajyothi M Siddappa1,2, Erin Morris3, Michael D Evans4
1Neonatology Department of Pediatrics Hennepin Healthcare, Minneapolis, Minnesota, USA.
Insights
Infants with neonatal opioid withdrawal syndrome (NOWS) requiring treatment show decreased growth parameters. Polysubstance exposure is linked to poorer inpatient growth, while short-acting opioid exposure may improve it.
Area of Science:
- Neonatal care
- Pediatric growth and development
- Pharmacology
Background:
- Neonatal Opioid Withdrawal Syndrome (NOWS) affects infants exposed to opioids prenatally.
- Growth parameters are critical indicators of infant health and development.
- Understanding factors influencing growth in NOWS infants is essential for optimizing care.
Purpose of the Study:
- To assess inpatient growth parameter trajectories in infants treated for NOWS.
- To identify the influence of prenatal opioid exposure type and treatment characteristics on infant growth.
- To analyze growth patterns based on opioid exposure (short-acting, long-acting, polysubstance), treatment, and sex.
Main Methods:
- Retrospective chart review of term infants with NOWS admitted to the NICU (2012-2019).
- Analysis of intake (volume, calories) and growth parameters (weight, head circumference, length Z-scores).
- Longitudinal mixed-effects models used to compare growth patterns across exposure and treatment groups.
Main Results:
- Infants with NOWS showed decreased Z-scores for weight, length, and head circumference from birth to discharge.
- Polysubstance exposure was associated with decreased length and head circumference Z-scores.
- Short-acting opioid exposure correlated with improved weight Z-scores near discharge; clonidine adjunct therapy also improved weight trends.
- Male infants exhibited lower weight and length Z-scores at Day 28 compared to females.
Conclusions:
- Infants with NOWS requiring pharmacologic treatment experience diminished inpatient growth.
- Prenatal polysubstance exposure poses a significant risk for poorer growth outcomes in NOWS infants.
- Growth trajectories vary based on opioid exposure type, with potential benefits from short-acting opioid exposure and adjunct clonidine.
Abstract:
Aim: To assess inpatient growth parameter trajectories and to identify the type of opioid exposure and treatment characteristics influencing growth parameters of infants admitted to the newborn intensive care unit (NICU) for pharmacological treatment of neonatal opioid withdrawal syndrome (NOWS). Methods: Charts of term infants with NOWS admitted to NICU from 2012 to 2019, who received pharmacologic treatment, were reviewed. Intake (volume: mL/kg/day; calorie: kcal/kg/day) and growth parameter trajectories (weight, head circumference, and length) were analyzed based on the type of prenatal opioid exposure (short-acting opioids (SAOs), long-acting opioids (LAOs), and polysubstance), pharmacologic treatment, and sex. Growth measurement patterns over time were compared between groups using longitudinal mixed-effects models. Results: One hundred nineteen infants were included in the study with median birth weight Z-score of -0.19 at birth and decreased to a median of -0.72 at discharge. Exposure to SAO was associated with an increase in Z-scores nearing discharge across all growth parameters (Z-score for weight p = 0.03). Polysubstance exposure was associated with a decrease in Z-scores for length and head circumference throughout hospitalization. Infants with adjunct clonidine treatment had an increase in Z-score for weight trends. Male infants had a decrease in Z-scores for weight (male -0.96, female -0.59, interaction p = 0.06) and length (male -1.17, female -0.57, interaction p = 0.003) at Day 28. Despite the difference in growth trajectories, intake in terms of amount (mL/kg/day) and calorie intake (kcal/kg/day) was similar based on prenatal exposure, treatment, and sex. Conclusion: Infants with NOWS requiring pharmacologic treatment have a decrease in Z-scores for weight, length, and head circumference at birth and at hospital discharge. Infants with prenatal polysubstance exposure were at particular risk for poorer inpatient growth relative to infants exposed to SAO and LAO, indicated by lower Z-scores for length and occipital frontal circumference (OFC).
More Related Videos
Related Concept Videos
Factors Affecting Drug Response: Overview
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Opioid Analgesics: Morphine and Other Natural Cogeners
Analgesia and Pain Management
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...

